Skip to main content

Susan Kay Murphy, PhD

Murphy
Associate Professor in Obstetrics and Gynecology
Campus Mail: 701 W. Main Street, Suite 510, Room 5140, Durham, NC 27701
Phone: (919) 681-3423
Email: susan.murphy@duke.edu

My research interests are largely centered around epigenetics and the role of epigenetic modifications in health and disease. My research projects include studies of gynecologic malignancies, including working on approaches to target ovarian cancer cells that survive chemotherapy and later give rise to recurrent disease.  I have ongoing collaborative projects in which we investigate the nature of the Developmental Origins of Health and Disease (DOHaD) hypothesis. DOHaD reflects the idea that our early environment plays an important part in shaping our risk of developing neurodevelopmental disorders or other chronic health problems. I am currently focused on preconception exposures in males with studies of the impact of cannabis use on the sperm epigenome and heritability of these effects. My lab is also working on the effects of in utero exposures, with our primary work revolving around the Newborn Epigenetics STudy (NEST), a mother-infant dyad cohort recruited from central North Carolina between 2005 and 2011 and whom we have followed since early pregnancy.

Education and Training

  • Ph.D., Wake Forest University, 1998
  • B.A., University of North Carolina - Charlotte, 1992

Selected Grants and Awards

Publications

Vidal, Adriana C., Susan K. Murphy, Brenda Y. Hernandez, Brandi Vasquez, John A. Bartlett, Olola Oneko, Pendo Mlay, et al. “Distribution of HPV genotypes in cervical intraepithelial lesions and cervical cancer in Tanzanian women.” Infect Agent Cancer 6, no. 1 (November 14, 2011): 20. https://doi.org/10.1186/1750-9378-6-20.

Full Text

Alvarez Secord, Angeles, Kathleen M. Darcy, Alan Hutson, Zhiqing Huang, Paula S. Lee, Elizabeth L. Jewell, Laura J. Havrilesky, Maurie Markman, Franco Muggia, and Susan K. Murphy. “The regulation of MASPIN expression in epithelial ovarian cancer: association with p53 status, and MASPIN promoter methylation: a gynecologic oncology group study.” Gynecol Oncol 123, no. 2 (November 2011): 314–19. https://doi.org/10.1016/j.ygyno.2011.08.003.

Full Text

Soubry, A., Sk Murphy, Z. Huang, A. Murtha, Jm Schildkraut, Rl Jirtle, F. Wang, et al. “The effects of depression and use of antidepressive medicines during pregnancy on the methylation status of the IGF2 imprinted control regions in the offspring.” Clin Epigenetics 3 (October 26, 2011): 2. https://doi.org/10.1186/1868-7083-3-2.

Full Text

Hoyo, Cathrine, Amy P. Murtha, Joellen M. Schildkraut, Randy L. Jirtle, Wendy Demark-Wahnefried, Michele R. Forman, Edwin S. Iversen, et al. “Methylation variation at IGF2 differentially methylated regions and maternal folic acid use before and during pregnancy.” Epigenetics 6, no. 7 (July 2011): 928–36. https://doi.org/10.4161/epi.6.7.16263.

Full Text

Zhang, Aiping, David A. Skaar, Yue Li, Dale Huang, Thomas M. Price, Susan K. Murphy, and Randy L. Jirtle. “Novel retrotransposed imprinted locus identified at human 6p25.” Nucleic Acids Res 39, no. 13 (July 2011): 5388–5400. https://doi.org/10.1093/nar/gkr108.

Full Text

Soubry, Adelheid, Susan K. Murphy, Zhiqing Huang, Amy Murtha, Joellen M. Schildkraut, Randy L. Jirtle, Frances Wang, et al. “Abstract 2754: Maternal use of antidepressants in pregnancy is associated with hypermethylation at theIGF2imprinted control regions in the offspring in a race-dependent fashion.” Epidemiology, April 15, 2011. https://doi.org/10.1158/1538-7445.am2011-2754.

Full Text

Huang, Zhiqing, Ken Yamaguchi, Andrew Berchuck, and Susan K. Murphy. “Abstract 3014: Quantitative accuracy of Illumina HumanMethylation27 Infinium BeadChip data assessed by pyrosequencing.” Cellular and Molecular Biology, April 15, 2011. https://doi.org/10.1158/1538-7445.am2011-3014.

Full Text

Teoh, Deanna, Tina A. Ayeni, Jennifer M. Rubatt, David J. Adams, Lisa Grace, Mark D. Starr, William T. Barry, Andrew Berchuck, Susan K. Murphy, and Angeles Alvarez Secord. “Dasatinib (BMS-35482) has synergistic activity with paclitaxel and carboplatin in ovarian cancer cells.” Gynecol Oncol 121, no. 1 (April 2011): 187–92. https://doi.org/10.1016/j.ygyno.2010.11.017.

Full Text

Kang, Hyun Sook, Tsukasa Baba, Masaki Mandai, Noriomi Matsumura, Junzo Hamanishi, Budiman Kharma, Eiji Kondoh, et al. “GPR54 is a target for suppression of metastasis in endometrial cancer.” Mol Cancer Ther 10, no. 4 (April 2011): 580–90. https://doi.org/10.1158/1535-7163.MCT-10-0763.

Full Text

Sfakianos, G., J. Yan, R. Whitaker, S. Murphy, and A. Berchuck. “Concordant gene expression profiles in matched primary and recurrent serous ovarian cancers predict platinum response.” Gynecologic Oncology 120 (March 2011): S46–S46. https://doi.org/10.1016/j.ygyno.2010.12.112.

Full Text

Pages